If E3 proteins such as RNF182 and TRIM9, which are specifically expressed in the central nervous system, can be linked to target proteins, then it may be possible to develop therapeutic drugs for neurodegenerative diseases with minimal side effects (Bekes et al., 2022). This evidence concerns the gene TRIM9 and neurodegenerative disease.